Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer
Recruitment status was: Recruiting
The primary end point of the study is confirmed objective response rate (complete response [CR] and partial response [PR]). A response rate of 80 percent for cetuximab plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (P-HDFL) chemotherapy is assumed. The Simon two-stage design will be used for P1 - P0 = 0.20. The response rates of interest are P0 = 60% and P1 = 80%. The investigators will reject cetuximab plus P-HDFL chemotherapy if the response rate is 8/13 at the first stage, and will reject the cetuximab plus P-HDFL chemotherapy if the response rate is 25/35 at the second stage. If there are more than 8 responses in 13 patients in the first stage, the study will continue to a total of 35 patients in the second stage. If there are more than 25 responses in 35 patients in the second stage, this treatment will be acceptable with a p-value of 0.05 and of 0.20. Evaluable patients for response will be those who received at least 4 doses of cetuximab (i.e. one cycle of protocol treatment). All enrolled patients will be subjected to toxicity evaluations.
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors). The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
The analysis of response to treatment will be restricted to the eligible patients with at least one measurable lesion. The safety analysis will be restricted to the patients who received at least one cycle of the administered chemotherapy. The time-to-event end points will be estimated using the method of Kaplan and Meier and based on the intent-to-treat principle. Overall survival will be defined as the time interval between the date of study entry and the date of death. Progression-free survival will be defined as the time interval between the date of study entry and the date of disease progression or death, whichever occurred first. Duration of response will be defined as the time interval between the date of initial objective response and the date of disease progression, which is only for responders. If the event is not yet observed at the time of the last record, the patient will be censored at that time point.
Drug: Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer|
- The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).
- The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
|Study Start Date:||June 2006|
|Primary Completion Date:||March 2007 (Final data collection date for primary outcome measure)|
Non-resectable gastric cancer is an incurable disease. Systemic chemotherapy confers prolongation of survival and improvement of quality of life. Regimens containing cisplatin and 5-fluorouracil (5-FU) are widely adopted in the world. A P-HDFL regimen, based primarily on weekly 24-hour infusion of cisplatin and high-dose 5-FU and leucovorin, is commonly used in Taiwan for patients with advanced gastric cancer; the overall response rate is around 60% (45%-76%, 95% C.I.), and the patients' compliance is excellent.
Expression of EGF and EGFR was detected in about 62.1% and 51.5% gastric cancer tissues, respectively. Tumors with simultaneous expression of EGF, TGF-alpha, EGFR and p185c-erbB-2 were associated with a high BrdU labeling index, rapid tumor growth, and an unfavorable outcome. Teramoto et al. have shown a dose-dependent growth inhibition of an anti-EGFR monoclonal antibody (MoAb 528) on EGFR-overexpressing human gastric cancer cells, both in vitro and in vivo. We have recently demonstrated that cetuximab is cytotoxic to human gastric cancer cells, and cetuximab has a chemo-sensitizing effect for cisplatin and 5-FU in human gastric cancer cells (Yeh et al, unpublished observation). We hypothesize that the combination of cetuximab with P-HDFL will further improve the efficacy of the latter on advanced gastric cancer.
This is a multi-center, prospective phase II trial. Patients with histologically proven nonresectable or recurrent/metastatic gastric adenocarcinoma, with at least one measurable lesion, no prior chemotherapy or radiotherapy, and adequate baseline organ functions will be eligible. Cetuximab (Erbitux; Merck, Germany) 400 mg/m2 will be given as an intravenous (IV) infusion, initially (i.e., day 1 of cycle 1); and then followed by weekly IV infusions of cetuximab 250 mg/m2 (i.e., days 8, 15, 22 of cycle 1, and days 1, 8, 15, 22 of cycle 2 and subsequent 28-day cycles). Cisplatin will be given as a 24-hour continuous IV infusion in a dose of 35 mg/m2/day, admixing with 5-FU 2,000 mg/m2 and leucovorin (folinic acid) 300 mg/m2, day 1 and day 8. A 24-hour continuous IV infusion of 5-FU 2,000 mg/m2 and leucovorin 300 mg/m2 will be given on day 15. The cycles will be repeated every 28 days, and the response evaluation will be performed every two cycles and at the end of protocol treatment. Confirmed objective response rate by RECIST (Response Evaluation Criteria in Solid Tumors) will be the primary end-point. Using the Simon two-stage design for phase II study (P1 - P0 = 0.20 with the response rates of interest being P0 = 60% and P1 = 80%), a total of 35 patients are planned to be enrolled in an estimated enrollment period of 12 to 18 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00384878
|Contact: Kun Huei Yeh, Ph.D.||886-2-89667000 ext firstname.lastname@example.org|
|Kun Huei Yeh, Ph.D||Recruiting|
|Taipei, Ban-Ciao, Taiwan, 220|
|Contact: Kun Huei Yeh, Ph.D. 886-2-89667000 ext 1611 email@example.com|
|Principal Investigator:||Kun Huei Yeh, Ph.D.||Far Eastern Memorial Hospital|